APOE and atherosclerosis: In contrast, treatment of ApoE−/− mice with human rIL-35 increased circulating and local Treg levels, inhibited the Th17 immune response, and reduced plaque size, suggesting that IL-35 alters the Th17/Treg balance by upregulating Treg immune responses, thereby attenuating atherosclerosis (99).